{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:01:43Z","timestamp":1791615703909,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010438","name":"Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu","doi-asserted-by":"publisher","award":["NMN0000060"],"award-info":[{"award-number":["NMN0000060"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97792-9","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:17:02Z","timestamp":1744791422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Low serum neopterin early indicates durable benefits of atezolizumab and pembrolizumab therapy in advanced lung cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-4716","authenticated-orcid":false,"given":"Anna","family":"Siemi\u0105tkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7236-5023","authenticated-orcid":false,"given":"Barbara","family":"Ku\u017anar-Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-5861","authenticated-orcid":false,"given":"Maciej","family":"Bryl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-4784","authenticated-orcid":false,"given":"Katarzyna","family":"Kosicka-Noworzy\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Przyby\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Go\u0142da-Gocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6611-5789","authenticated-orcid":false,"given":"Franciszek K.","family":"G\u0142\u00f3wka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"97792_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106939","volume":"88","author":"L Li","year":"2020","unstructured":"Li, L. et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int. Immunopharmacol. 88, 106939 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"97792_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00159","author":"S Saab","year":"2020","unstructured":"Saab, S. et al. Insights into lung cancer immune-based biology, prevention, and treatment. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00159 (2020).","journal-title":"Front. Immunol."},{"key":"97792_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/ijms21020597","volume":"21","author":"K Kunimasa","year":"2020","unstructured":"Kunimasa, K. & Goto, T. Immunosurveillance and immunoediting of lung cancer: Current perspectives and challenges. Int. J. Mol. Sci. 21, 597 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"97792_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jtho.2021.03.017","volume":"16","author":"RM Memmott","year":"2021","unstructured":"Memmott, R. M., Wolfe, A. R., Carbone, D. P. & Williams, T. M. Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors. J. Thorac. Oncol. 16, 1086\u20131098 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"97792_CR5","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/jcm9051362","volume":"9","author":"K Onoi","year":"2020","unstructured":"Onoi, K. et al. Immune checkpoint inhibitors for lung cancer treatment: A review. J. Clin. Med. 9, 1362 (2020).","journal-title":"J. Clin. Med."},{"key":"97792_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1129465","author":"S Zhou","year":"2023","unstructured":"Zhou, S. & Yang, H. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1129465 (2023).","journal-title":"Front. Immunol."},{"key":"97792_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-024-02969-1","volume":"43","author":"Y-T Tsai","year":"2024","unstructured":"Tsai, Y.-T., Schlom, J. & Donahue, R. N. Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. J. Exp. Clin. Cancer Res. 43, 82 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"97792_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171649","author":"J Ancel","year":"2023","unstructured":"Ancel, J. et al. Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1171649 (2023).","journal-title":"Front. Immunol."},{"key":"97792_CR9","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.3390\/cancers13153702","volume":"13","author":"A Siemi\u0105tkowska","year":"2021","unstructured":"Siemi\u0105tkowska, A. et al. Serum sCD25 protein as a predictor of lack of long-term benefits from immunotherapy in non-small cell lung cancer: A pilot study. Cancers 13, 3702 (2021).","journal-title":"Cancers"},{"key":"97792_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00262-023-03377-8","volume":"72","author":"A Siemi\u0105tkowska","year":"2023","unstructured":"Siemi\u0105tkowska, A. et al. Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab. Cancer Immunol. Immunother. 72, 1853\u20131863 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"97792_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006462","volume":"11","author":"M Zheng","year":"2023","unstructured":"Zheng, M. Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: Moving toward optimizing antitumor immunity. J. Immunother. Cancer 11, e006462 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"97792_CR12","doi-asserted-by":"publisher","first-page":"1516737","DOI":"10.3389\/fimmu.2024.1516737","volume":"15","author":"C Tang","year":"2024","unstructured":"Tang, C. et al. The systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model. Front. Immunol. 15, 1516737 (2024).","journal-title":"Front. Immunol."},{"key":"97792_CR13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.3390\/cells11121979","volume":"11","author":"J Austermann","year":"2022","unstructured":"Austermann, J., Roth, J. & Barczyk-Kahlert, K. The good and the bad: Monocytes\u2019 and macrophages\u2019 diverse functions in inflammation. Cells 11, 1979 (2022).","journal-title":"Cells"},{"key":"97792_CR14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.21037\/tlcr-20-1241","volume":"10","author":"SS Sedighzadeh","year":"2021","unstructured":"Sedighzadeh, S. S., Khoshbin, A. P., Razi, S., Keshavarz-Fathi, M. & Rezaei, N. A narrative review of tumor-associated macrophages in lung cancer: Regulation of macrophage polarization and therapeutic implications. Transl. Lung Cancer Res. 10, 1889\u20131916 (2021).","journal-title":"Transl. Lung Cancer Res."},{"key":"97792_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/atm.2017.06.29","volume":"5","author":"B Melichar","year":"2017","unstructured":"Melichar, B. et al. Neopterin as a biomarker of immune response in cancer patients. Ann. Transl. Med. 5, 280 (2017).","journal-title":"Ann. Transl. Med."},{"key":"97792_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","volume":"18","author":"A Sica","year":"2008","unstructured":"Sica, A. et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349\u2013355 (2008).","journal-title":"Semin. Cancer Biol."},{"key":"97792_CR17","doi-asserted-by":"publisher","first-page":"34217","DOI":"10.18632\/oncotarget.9079","volume":"7","author":"J Mei","year":"2016","unstructured":"Mei, J. et al. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis. Oncotarget 7, 34217\u201334228 (2016).","journal-title":"Oncotarget"},{"key":"97792_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2174\/1389200024605082","volume":"3","author":"C Murr","year":"2002","unstructured":"Murr, C., Widner, B., Wirleitner, B. & Fuchs, D. Neopterin as a marker for immune system activation. Curr. Drug Metab. 3, 175\u2013187 (2002).","journal-title":"Curr. Drug Metab."},{"key":"97792_CR19","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3390\/biomedicines11051294","volume":"11","author":"O Heneberk","year":"2023","unstructured":"Heneberk, O., Wurfelova, E. & Radochova, V. Neopterin, the cell-mediated immune response biomarker, in inflammatory periodontal diseases: A narrative review of a more than fifty years old biomarker. Biomedicines 11, 1294 (2023).","journal-title":"Biomedicines"},{"key":"97792_CR20","first-page":"113","volume":"31","author":"ZJ El-Akawi","year":"2010","unstructured":"El-Akawi, Z. J., Abu-Awad, A. M., Sharara, A. M. & Khader, Y. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients. Neuro Endocrinol. Lett. 31, 113\u2013116 (2010).","journal-title":"Neuro Endocrinol. Lett."},{"key":"97792_CR21","first-page":"771","volume":"7","author":"I Yuksekol","year":"2003","unstructured":"Yuksekol, I. et al. Urinary neopterin measurement as a non-invasive diagnostic method in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis. 7, 771\u2013776 (2003).","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"key":"97792_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1365-2354.2009.01122.x","volume":"19","author":"AB Engin","year":"2010","unstructured":"Engin, A. B., Ozkan, Y., Fuchs, D. & Yardim-Akaydin, S. Increased tryptophan degradation in patients with bronchus carcinoma. Eur. J. Cancer Care (Engl.) 19, 803\u2013808 (2010).","journal-title":"Eur. J. Cancer Care (Engl.)"},{"key":"97792_CR23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1515\/pteridines-2020-0017","volume":"31","author":"S Yalcin","year":"2020","unstructured":"Yalcin, S. et al. Prognostic effects of SuPAR and neopterin levels on patients with lung cancer. Pteridines 31, 136\u2013141 (2020).","journal-title":"Pteridines"},{"key":"97792_CR24","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1378\/chest.119.3.776","volume":"119","author":"KH Mohamed","year":"2001","unstructured":"Mohamed, K. H. et al. BAL neopterin: A novel marker for cell-mediated immunity in patients with pulmonary tuberculosis and lung cancer. Chest 119, 776\u2013780 (2001).","journal-title":"Chest"},{"key":"97792_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2022.11495","volume":"24","author":"AA Musaelyan","year":"2022","unstructured":"Musaelyan, A. A. et al. Inflammatory and autoimmune predictive markers of response to anti-PD-1\/PD-L1 therapy in NSCLC and melanoma. Exp. Ther. Med. 24, 1\u201312 (2022).","journal-title":"Exp. Ther. Med."},{"key":"97792_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004420","volume":"10","author":"K Azuma","year":"2022","unstructured":"Azuma, K. et al. Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: A pilot cohort study for developing a prognostic multivariate model. J. Immunother. Cancer 10, e004420 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"97792_CR27","first-page":"393","volume":"37","author":"M Spisarova","year":"2023","unstructured":"Spisarova, M. et al. Biomarkers of inflammation and progression during immunotherapy in patients with metastatic renal cell carcinoma. Vivo Athens Greece 37, 393\u2013399 (2023).","journal-title":"Vivo Athens Greece"},{"key":"97792_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"97792_CR29","unstructured":"Centers for Disease Control and Prevention. Tobacco use information - glossary. https:\/\/www.cdc.gov\/nchs\/nhis\/tobacco\/tobacco_glossary.htm."},{"key":"97792_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1751-1097.2008.00450.x","volume":"85","author":"M Vignoni","year":"2009","unstructured":"Vignoni, M., Cabrerizo, F. M., Lorente, C. & Thomas, A. H. New results on the photochemistry of biopterin and neopterin in aqueous solution. Photochem. Photobiol. 85, 365\u2013373 (2009).","journal-title":"Photochem. Photobiol."},{"key":"97792_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0009-8981(02)00076-1","volume":"1\u20132","author":"A Laich","year":"2002","unstructured":"Laich, A., Neurauter, G., Wirleitner, B. & Fuchs, D. Degradation of serum neopterin during daylight exposure. Clin. Chim. Acta 1\u20132, 175\u2013178 (2002).","journal-title":"Clin. Chim. Acta"},{"key":"97792_CR32","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/clinchem\/33.11.2028","volume":"33","author":"ER Werner","year":"1987","unstructured":"Werner, E. R., Fuchs, D., Hausen, A., Reibnegger, G. & Wachter, H. Simultaneous determination of neopterin and creatinine in serum with solid-phase extraction and on-line elution liquid chromatography. Clin. Chem. 33, 2028\u20132033 (1987).","journal-title":"Clin. Chem."},{"key":"97792_CR33","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/rcm.4013","volume":"23","author":"\u00d8 Midttun","year":"2009","unstructured":"Midttun, \u00d8., Hustad, S. & Ueland, P. M. Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammation in human plasma by liquid chromatography\/tandem mass spectrometry. Rapid Commun. Mass Spectrom. RCM 23, 1371\u20131379 (2009).","journal-title":"Rapid Commun. Mass Spectrom. RCM"},{"key":"97792_CR34","unstructured":"European Medicines Agency. ICH guideline M10 on bioanalytical method validation\u2014Step 5. https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline."},{"key":"97792_CR35","doi-asserted-by":"publisher","first-page":"pkab012","DOI":"10.1093\/jncics\/pkab012","volume":"5","author":"J Man","year":"2021","unstructured":"Man, J., Millican, J., Mulvey, A., Gebski, V. & Hui, R. Response rate and survival at key timepoints with PD-1 blockade vs chemotherapy in PD-L1 subgroups: Meta-analysis of metastatic NSCLC trials. JNCI Cancer Spectr. 5, pkab012 (2021).","journal-title":"JNCI Cancer Spectr."},{"key":"97792_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/oxfordjournals.jbchem.a128513","volume":"61","author":"A Sakurai","year":"1967","unstructured":"Sakurai, A. & Goto, M. Neopterin: Isolation from human urine. J. Biochem. (Tokyo) 61, 142\u2013145 (1967).","journal-title":"J. Biochem. (Tokyo)"},{"key":"97792_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1515\/pterid-2015-0020","volume":"27","author":"T Baydar","year":"2016","unstructured":"Baydar, T., Kemer, O. E., Kilicarslan, B., Cardak, A. & Girgin, G. Detection of neopterin in tear samples. Pteridines 27, 13\u201316 (2016).","journal-title":"Pteridines"},{"key":"97792_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/096120339500400107","volume":"4","author":"MY Samsonov","year":"1995","unstructured":"Samsonov, M. Y. et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 4, 29\u201332 (1995).","journal-title":"Lupus"},{"key":"97792_CR39","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/biology11071033","volume":"11","author":"A Crintea","year":"2022","unstructured":"Crintea, A. et al. Assessment of specific tumoral markers, inflammatory status, and vitamin D metabolism before and after the first chemotherapy cycle in patients with lung cancer. Biology 11, 1033 (2022).","journal-title":"Biology"},{"key":"97792_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0924-9338(96)80345-2","volume":"10","author":"M Maes","year":"1995","unstructured":"Maes, M., Bosmans, E., Scharp\u00e9, S., D\u2019Hondt, P. & Desnyder, R. Plasma soluble interleukin-2-receptor in depression: Relationships to plasma neopterin and serum IL-2 concentrations and HPA-axis activity. Eur. Psychiatry 10, 397\u2013403 (1995).","journal-title":"Eur. Psychiatry"},{"key":"97792_CR41","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0003-4975(00)01840-3","volume":"70","author":"R Prommegger","year":"2000","unstructured":"Prommegger, R. et al. Neopterin: A prognostic variable in operations for lung cancer. Ann. Thorac. Surg. 70, 1861\u20131864 (2000).","journal-title":"Ann. Thorac. Surg."},{"key":"97792_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1515\/pteridines.2007.18.1.95","volume":"18","author":"H Kalabova","year":"2007","unstructured":"Kalabova, H. et al. Urinary neopterin in patients treated with gefitinib. Pteridines 18, 95\u2013100 (2007).","journal-title":"Pteridines"},{"key":"97792_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1515\/pterid-2017-0018","volume":"28","author":"J Mergancov\u00e1","year":"2017","unstructured":"Mergancov\u00e1, J. et al. Concentrations of neopterin, kynurenine and tryptophan in wound secretions of patients with breast cancer and malignant melanoma: A pilot study. Pteridines 28, 205\u2013211 (2017).","journal-title":"Pteridines"},{"key":"97792_CR44","doi-asserted-by":"crossref","unstructured":"Yan, J. et al. CSF neopterin, quinolinic acid and kynurenine\/tryptophan ratio are biomarkers of active neuroinflammation. eBioMedicine 91 (2023).","DOI":"10.1016\/j.ebiom.2023.104589"},{"key":"97792_CR45","doi-asserted-by":"crossref","unstructured":"Kronberger, P. et al. Predictive value of urinary neopterin in patients with lung cancer. 33, 831\u2013838 (1995).","DOI":"10.1515\/cclm.1995.33.11.831"},{"key":"97792_CR46","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/0277-5379(91)90271-E","volume":"27","author":"P Lissoni","year":"1991","unstructured":"Lissoni, P. et al. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur. J. Cancer Clin. Oncol. 27, 1014\u20131016 (1991).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"97792_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000282469","volume":"50","author":"S Kleinknecht","year":"2010","unstructured":"Kleinknecht, S., Bichler, K.-H. & Strohmaier, W. L. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma. Urol. Int. 50, 121\u2013128 (2010).","journal-title":"Urol. Int."},{"key":"97792_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1006\/clin.1994.1035","volume":"70","author":"K H\u00f6barth","year":"1994","unstructured":"H\u00f6barth, K., Szabo, N., Hallas, A., Aulitzky, W. & Marberger, M. Serum neopterin as a parameter for monitoring the course of renal cell carcinoma during interferon-gamma therapy. Clin. Immunol. Immunopathol. 70, 241\u2013244 (1994).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"97792_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0165-1781(03)00113-6","volume":"119","author":"AR Van Gool","year":"2003","unstructured":"Van Gool, A. R. et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res. 119, 125\u2013132 (2003).","journal-title":"Psychiatry Res."},{"key":"97792_CR50","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/gerona\/glq066","volume":"65A","author":"ME Spencer","year":"2010","unstructured":"Spencer, M. E. et al. Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J. Gerontol. Ser. A 65A, 858\u2013865 (2010).","journal-title":"J. Gerontol. Ser. A"},{"key":"97792_CR51","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/clinchem\/48.4.643","volume":"48","author":"H Schennach","year":"2002","unstructured":"Schennach, H. et al. Factors influencing serum neopterin concentrations in a population of blood donors. Clin. Chem. 48, 643\u2013645 (2002).","journal-title":"Clin. Chem."},{"key":"97792_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1515\/pteridines.2000.11.4.133","volume":"11","author":"N Yoshida","year":"2000","unstructured":"Yoshida, N. et al. Serum Neopterin levels in renal cell carcinoma. Pteridines 11, 133\u2013136 (2000).","journal-title":"Pteridines"},{"key":"97792_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12032-008-9054-2","volume":"25","author":"Y Yildirim","year":"2008","unstructured":"Yildirim, Y. et al. Serum neopterin levels in patients with breast cancer. Med. Oncol. 25, 403\u2013407 (2008).","journal-title":"Med. Oncol."},{"key":"97792_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1212\/WNL.41.1.69","volume":"41","author":"DE Griffin","year":"1991","unstructured":"Griffin, D. E., McArthur, J. C. & Cornblath, D. R. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 41, 69\u201374 (1991).","journal-title":"Neurology"},{"key":"97792_CR55","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/BF00180281","volume":"70","author":"GP Tilz","year":"1992","unstructured":"Tilz, G. P. et al. Association between serum-soluble CD8 levels and parameters of immune activation in patients with human immunodeficiency virus infection. Clin. Investig. 70, 662\u2013664 (1992).","journal-title":"Clin. Investig."},{"key":"97792_CR56","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/196432","volume":"2013","author":"M Eisenhut","year":"2013","unstructured":"Eisenhut, M. Neopterin in Diagnosis and Monitoring of Infectious Diseases. J. Biomark. 2013, 196432 (2013).","journal-title":"J. Biomark."},{"key":"97792_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2022.03.002","volume":"104","author":"Y Rasmi","year":"2022","unstructured":"Rasmi, Y. et al. The importance of neopterin in COVID-19: The prognostic value and relation with the disease severity. Clin. Biochem. 104, 1\u201312 (2022).","journal-title":"Clin. Biochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97792-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97792-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:02:28Z","timestamp":1744797748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97792-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97792"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97792-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MB\u2014honoraria, consulting or advisory role and travel, accommodations, expenses from Boehringer Ingelheim, Roche\/Genentech, MSD, Bristol-Myers Squibb, AstraZeneca, Takeda, Novartis, Pfizer, Sanofi; AS, BKK, KKN, PP, IGG, and FKG declare no conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13078"}}